Efficacy and safety of oral continuous low‐dose versus short‐term high‐dose vitamin D: a prospective randomised trial conducted in a clinical setting

2010 ◽  
Vol 192 (12) ◽  
pp. 686-689 ◽  
Author(s):  
Kathryn L Hackman ◽  
Claudia Gagnon ◽  
Roisin K Briscoe ◽  
Simon Lam ◽  
Mahesan Anpalahan ◽  
...  
Keyword(s):  
Vitamin D ◽  
Clinical Setting ◽  
Low Dose ◽  
Randomised Trial ◽  
High Dose ◽  
Efficacy And Safety ◽  
Short Term ◽  
Prospective Randomised Trial ◽  
High Dose Vitamin

Sa1779 Vitamin D Modulates T Cell-Mediated Immunity: Results From a Randomized Controlled Trial of Low-Dose and High-Dose Vitamin D3

2014 ◽  
Vol 146 (5) ◽  
pp. S-294 ◽  
Author(s):  
Gauree G. Konijeti ◽  
Matthew R. Boylan ◽  
Yanna Song ◽  
Pankaj Arora ◽  
Frank E. Harrell ◽  
...  
Keyword(s):  
Vitamin D ◽  
Randomized Controlled Trial ◽  
T Cell ◽  
Vitamin D3 ◽  
Low Dose ◽  
Controlled Trial ◽  
High Dose ◽  
Cell Mediated Immunity ◽  
Randomized Controlled ◽  
High Dose Vitamin

scholarly journals High-Dose versus Low-Dose Vitamin D Supplementation and Arterial Stiffness among Individuals with Prehypertension and Vitamin D Deficiency

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Amanda Zaleski ◽  
Gregory Panza ◽  
Heather Swales ◽  
Pankaj Arora ◽  
Christopher Newton-Cheh ◽  
...  
Keyword(s):  
Vitamin D ◽  
Arterial Stiffness ◽  
Pulse Wave Velocity ◽  
Vitamin D Deficiency ◽  
Wave Velocity ◽  
Low Dose ◽  
Pulse Wave ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
High Dose Vitamin

Introduction. Vitamin D deficiency is associated with the onset and progression of hypertension and cardiovascular disease (CVD). However, mechanisms underlying vitamin D deficiency-mediated increased risk of CVD remain unknown. We sought to examine the differential effect of high-dose versus low-dose vitamin D supplementation on markers of arterial stiffness among ~40 vitamin D deficient adults with prehypertension.Methods. Participants were randomized to high-dose (4000 IU/d) versus low-dose (400 IU/d) oral vitamin D3 for 6 months. 24 hr ambulatory blood pressure (BP), carotid-femoral pulse wave velocity, and pulse wave analyses were obtained at baseline and after 6 months of vitamin D supplementation.Results. There were no changes in resting BP or pulse wave velocity over 6 mo regardless of vitamin D dose (allp>0.202). High-dose vitamin D decreased augmentation index and pressure by 12.3 ± 5.3% (p=0.047) and 4.0 ± 1.5 mmHg (p=0.02), respectively. However, these decreases in arterial stiffness were not associated with increases in serum 25-hydroxyvitamin D over 6 mo (p=0.425).Conclusion. High-dose vitamin D supplementation appears to lower surrogate measures of arterial stiffness but not indices of central pulse wave velocity.Clinical Trial Registration. This trial is registered with www.clinicaltrials.gov (Unique Identifier:NCT01240512).

Impact of high-dose vitamin d supplementation on short physical performance battery and bioelectrical impedance analysis in older patients with prostate cancer on ADT.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e23106-e23106 ◽  
Author(s):  
Julia Ellen Inglis ◽  
Eva Culakova ◽  
Richard Francis Dunne ◽  
Michelle Christine Janelsins ◽  
Po-Ju Lin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Phase Angle ◽  
Older Patients ◽  
Low Dose ◽  
Bioelectrical Impedance ◽  
Impedance Analysis ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
High Dose Vitamin

e23106 Background: Androgen deprivation therapy (ADT) is standard treatment for prostate cancer but may cause changes in body composition that lead to decreased physical function. Low vitamin D status is also associated with decreased functionality. The Short Physical Performance Battery (SPPB) is an objective assessment tool for evaluating functionality. The bioelectrical impedance analysis (BIA) is a portable tool for assessing lean mass and phase angle, a measure of nutrition status and frailty in chronic disease. Methods: This was a secondary analysis of a randomized controlled trial to assess the impact of high dose vitamin D in older patients (≥60 yrs) with prostate cancer on ADT. Patients with prostate cancer (N = 59, age 67.6 ± 5.4) with vitamin D insufficiency ( < 32 ng/ml) were randomized to high-dose vitamin D (n = 29, 600 IU/daily plus 50,000 IU/weekly) or low-dose vitamin D (n = 30, 600 IU/daily plus placebo weekly) for 24 weeks. SPPB tests and BIA were assessed at baseline, 12 weeks and 24 weeks. Phase angle values were calculated using atan(reactance/resistance) x (180°/π). A phase angle value < 5.7° is a valid cutoff for frailty in older men. Results: Serum analyses showed compliance with vitamin D intake (25-OH vitamin D change: high vitamin D = +32.0 ng/ml vs low dose RDA vitamin D = +4.3 ng/ml; p < .01). There were no difference at all three assessments for SPPB or lean mass between arms. The high-dose vitamin D group had wider phase angle values at 12 weeks (5.81º vs. 5.32º; p = .018) and 24 weeks (5.89º vs. 5.40º; p = .030). The low-dose group had phase angle values < 5.7º over the course of the study. At baseline, over 18% of patients had phase angle values below the 10th percentile of the general population matched on age and BMI. As vitamin D levels increased throughout the study, fewer patients fell below the 10th percentile. Conclusions: The high-dose vitamin D group maintained wider phase angle values over 24 weeks, while phase angle for the low-dose group decreased from baseline. High-dose vitamin D supplementation may impact factors related to phase angle and frailty in patients receiving ADT. Funding: NCI UGCA189961, R21CA175793, K07CA168911, and GR501293.

scholarly journals Maintaining Strong Bones: Strong Opinions, Little Evidence

2007 ◽  
Vol 7 (5) ◽  
pp. 123-124
Author(s):  
Donna C Bergen
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Low Dose ◽  
High Dose ◽  
Mineral Density ◽  
Age And Gender ◽  
Ambulatory Patients ◽  
And Gender ◽  
High Dose Vitamin

Two Randomized Vitamin D Trials in Ambulatory Patients on Anticonvulsants: Impact on Bone. Mikati MA, Dib L, Yamout B, Sawaya R, Rahi AC, Fuleihan Gel-H. Neurology 2006;67(11):2005–2014. OBJECTIVE: To investigate the effects of two doses of vitamin D given over 1 year on bone density in ambulatory patients on long-term antiepileptic drug (AED) therapy. METHODS: We conducted two parallel, randomized, controlled trials in 72 adults (18–54 years old) and 78 children and adolescents (10–18 years) on long-term AED therapy. They received either low-dose vitamin D 400 IU/day or high-dose vitamin D 4,000 IU/day (adults) and 2,000 IU/day (children/adolescents). Bone mineral density (BMD) was measured using dual-energy x-ray absorptiometry. RESULTS: In adults, baseline BMD was lower than that of age- and gender-matched controls vs either a Western or an ethnically identical population. After 1 year, there were significant increases in BMD at all skeletal sites compared to baseline in the high-, but not in the low-dose treatment group. However, BMD at 1 year remained below normal. In children, baseline BMD was normal vs age- and gender-matched controls and showed significant and comparable increases in both treatment groups. CONCLUSIONS: In ambulatory adults on antiepileptic drugs, high-dose vitamin D therapy substantially increased bone mineral density at several skeletal sites. In children, both doses resulted in comparable increases in bone mass.

scholarly journals The role of high-dose steroid therapy in Covid-19 pneumonia

2021 ◽  
Author(s):  
Ayperi Ozturk ◽  
Figen Ozturk Ergur ◽  
Suna Kavurgacı ◽  
Melahat Uzel Şener ◽  
Murat Yıldız
Keyword(s):  
Mortality Rate ◽  
Low Dose ◽  
High Dose ◽  
Efficacy And Safety ◽  
Short Term ◽  
High Dose Steroid ◽  
Younger Age ◽  
Observation Period

Introduction: Today, whereas hypoxemia and respiratory failure is the major challenging problem in the course of severe COVID-19 pneumonia, to control the disease at a mild-moderate stage or to stop the inflammation by recognizing the cytokine storm early should be the most prominent goal. We aimed to reveal the clinical efficacy and safety of short-term high-dose corticosteroids in severe COVID-19. Material and Methods: This retrospective observational study consisted of 54 patients who were given high-dose steroid (HDS (>250 mg/day methylprednisolone, 3 days.). Low-dose steroid (LDS) therapy (dexamethasone 8 mg ) was applied to all patients. HDS group was reviewed in terms of decreasing hospital mortality and preventing fibrosis development in follow-up. Results: During the observation period, out of 317 severe COVID-19 pneumonia hospitalized, HDS and LDS were administered to 54 and 216 patients, respectively. Higher body mass index, younger age, more oxygen need of patients at admission, and more need for advanced oxygen therapy during hospitalization were found in the HDS group (p<0.001). Furthermore, 18.5% of patients in the HDS group had need transfer to the intensive care unit whereas it was 3.8% in LDS (p<0.001). Additionally, the mortality rate was determined higher in the HDS group (25. 9% vs 9.9%, p<0.001). The HDS group had lower saturated O2 [IQR, 85% (76-89), p <0.001], and higher ferritin at admission. It was found that HDS was given simultaneously with the increased ferritin with deepening lymphopenia on the third and fifth days. There was no difference in fibrosis development between HDS patients receive and not (15.4% vs 26.2%, p=0.11) Conclusion: The use of HDS in hospitalized COVID-19 patients remains unclear. Along with this, our study demonstrated the use of high-dose corticosteroids might not be associated with a lower mortality rate among hospitalized severe COVID-19 patients.

Sign in / Sign up

Export Citation Format

Share Document